研究单位：[1]BeiGene[2]Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology华中科技大学同济医学院附属同济医院[3]Beijing Cancer Hospital[4]Chinese PLA General Hospital
研究目的：
The primary objective of this study was to evaluate the efficacy of tislelizumab assessed by Independent Review Committee (IRC) in participants with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Overall Response Rate (ORR) per the Lugano Classification
